Search

everythinglearnresearchcommunity

for

Search:↓

Women with only irregular periods or excess hair have a better hormone profile than those with full PCOS, but both groups are similar, indicating a need for better PCOS diagnosis methods.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

High levels of male hormones, insulin resistance, and obesity are closely linked and worsen polycystic ovary syndrome, but more research is needed to improve treatments.

Some women with acne have higher levels of free testosterone, which might suggest using hormonal treatments for acne.

Daughters of women with PCOS generally experience normal puberty but may have more body hair and different body fat distribution.

Most women with Polycystic Ovary Syndrome (PCOS) have skin issues like excessive hair, acne, or hair loss. Hormone imbalances are common, and age, certain hormones, and hormone ratios can predict acne. Obesity, infertility, and high cholesterol are also common in these women.

Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.

The engineered yeast strain BLYAS can quickly and sensitively detect androgenic chemicals.

Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.

A new method accurately measures nine specific hormones in human blood.

Mice without the enzyme HSD17B3 still produce normal testosterone, suggesting they have different ways to make it compared to humans.

Treating non-classic congenital adrenal hyperplasia is complex because the benefits of hormone treatment must be weighed against potential health risks.

Postmenopausal hyperandrogenism, a condition with symptoms like increased hair growth and acne, is usually caused by PCOS but can also be due to other factors. It's diagnosed by checking testosterone levels and treated either by removing the adrenal tumor or through antiandrogen therapy.

Androgens affect hair growth and shedding, with genetic and non-genetic factors influencing baldness.

FPHL causes hair loss in women due to genetics and hormones; minoxidil and anti-androgens are treatments, and early intervention is advised.

Copper deficiency may cause hair loss, and treating it could involve nutrition and hormones.

Treatments for hair loss vary, but cell-based options may be the future.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Genetics affect early female hair loss, severity depends on duration, and low ferritin levels not significant.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

The document concludes that sex hormones are crucial for mammalian reproduction, health, and behavior, and require more research for therapeutic use.

Female hair loss patients more likely to have dry eye and gland issues.

Male pattern baldness involves genetics, hormones, and needs better treatments.

Testosterone treatment in trans men increases body and facial hair and may lead to hair loss over time, but severe skin issues are rare.

DHEA stimulates skin oil glands and could help postmenopausal women, with potential for acne and excessive hair growth treatments.

Testosterone therapy is beneficial for women's health and does not cause masculinization or liver damage, and it protects the heart and breasts.

Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.

Finasteride reduces dihydrotestosterone, increases testosterone, and may treat hirsutism in women.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.